Overview

Heart Failure and Anemia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether increasing hemoglobin concentration in patients with heart failure and anemia will improve the patients' functional status, including exercise tolerance and New York Heart Association (NYHA) classification.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Treatments:
Darbepoetin alfa